Enobosarm preserved lean mass in patients receiving Wegovy for weight reduction

Shares of Florida-USA-based drug developer Veru (Nasdaq: VERU) plummeted more than 52% to $0.57 in pre-market activity today, despite the company releasing positive top-line results from the Phase IIb QUALITY clinical study.

The Phase IIb QUALITY clinical study was a multicenter, double-blind, placebo-controlled, randomized, dose-finding study to evaluate the safety and efficacy of enobosarm 3mg, and enobosarm 6mg, compared to placebo in 168 older patients, greater than 60 years of age, who are overweight or have obesity and who are receiving Wegovy(semaglutide), a GLP-1 receptor agonist (RA), for weight reduction.

Wegovy is Danish pharma major Novo Nordisk’s (NOV: N) blockbuster obesity drug that, alo ng with Eli Lilly’s (NYSE: LLY) tirzepatide (trade names Mounjaro and Zepbound), is leading the obesity treatment market that is forecast to grow to $150 billion in revenue in the next decade.